Show Summary Details
Page of

Disodium cromoglycate for allergic asthma 

Disodium cromoglycate for allergic asthma
Disodium cromoglycate for allergic asthma

Alan Edwards

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 02 March 2021

A double-blind cross-over sequential trial of a new antiallergic compound, disodium cromoglycate (‘FPL670’, ‘Intal’) was carried out over a period of 6 weeks in ten patients severely disabled with allergic bronchial asthma. There was a significant clinical improvement during administration of FPL670 plus isoprenaline in all patients compared with two periods in which isoprenaline alone was given. Spirometric improvement occurred in only four patients. Subsequent experience over periods up to 26 months with these and other patients has confirmed the therapeutic value and safety of FPL670 in the management of allergic bronchial asthma.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.